LDCoder®: The Product

Founder and CEO of Lundoch Diagnostics, Dr. Yang De Marinis (Assoc Prof, Prof), with her invention LDcoder®.

LDcoder® FACTS:

  • The first and only diabetes early risk detection blood test in the world.
  • Detects the precise risk of developing Type 2 diabetes within 4 years of any adult individual (>18 years old) at the time of the testing, incorporating genetics, life-style factors and physiological conditions.
  • It is composed of an AI machine-learning software together with patented blood biomarker analysis kits. The LDcoder® software is cloud-based with large data analysis and management capacity. The LDcoder® biomarker analysis kits are Enzyme-Linked Immunosorbent Assay (ELISA) kits.
  • The test is performed on a tiny amount of blood sample: 50 µL venepuncture blood plasma.
  • Patented technology.
  • CE-marked medical devices, and can be easily implemented in any clinical laboratories or centralized labs.
  • High performance with high accuracy (85.1%), in comparison to e.g. DNA diabetes test which could explain only ~15% of diabetes risk without taking life-style and physiology into consideration.
  • Developed at Lund University based on large international clinical studies performed on more than 8000 individuals followed for up to 20 years from 8 counties across Europe and the US.

LDcoder®: The Science

Scientific breakthrough: the discovery of blood biomarker for Type 2 diabetes early risk detection.

LDcoder® was developed based on large international clinical studies performed on more than 8000 individuals followed for up to 20 years from 8 counties. It is a fruitful collaboration between 22 institutes, hospitals and universities from Sweden, Finland, Germany, US, UK, France, Switzerland, Italy, Denmark and China. The study was led by Dr. Yang De Marinis, Associate Professor at Lund University and Professor at Shandong University, who is also the Founder and CEO of Lundoch Diagnostics.

The breakthrough discovery was published in the prestigious scientific journal Nature Communications, entitled ” Elevated circulating follistatin associates with an increased risk of type 2 diabetes”. This large international study revealed that higher levels of the protein follistatin predict diabetes many years before diagnosis, regardless of other known risk factors, such as age, body mass index (BMI), fasting blood glucose levels, diet or physical activity.

Read The Study